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In the present issue of the Journal of Thoracic Oncology, Matsumura et al.1 reported a retrospective unicentric study assessing the prognostic role of a pathological factor, 
lymphatic permeation, after non–small-cell lung cancer (NSCLC) resection. Lymphatic 
permeation was defined by the presence of floating tumor cells in vessels with no sup-
porting smooth muscles or with elastic fibers. The confirmation of the visualization of 
the lymphatic vessels was confirmed by immunohistochemical staining with anti–D2-40 
antibody. Lymphatic permeation was classified as ly0 in case of absence of lymphatic 
permeation, ly1 in the presence of intratumoral lymphatic permeation, and ly2 in the 
presence of extratumoral lymphatic permeation. In 1069 patients, lymphatic permeation 
was detected in 224 (21%), with 134 (12%) ly1 and 90 (9%) ly2. The 5-year overall sur-
vival rates of the ly0, ly1, and ly2 groups were 75%, 63%, and 34%, respectively, which 
were statistically significantly different. In multivariate analyses, ly2 appeared to be an 
independent poor prognostic factor.
Two questions may arise from those results: Should lymphatic permeation be 
incorporated in the staging classification? Is lymphatic permeation a potential useful 
marker for proposing adjuvant chemotherapy? By definition, lymphatic permeation can 
be today fully assessed only after surgery and requires careful microscopic examina-
tion of the removed piece. It is thus a factor to be considered for the pathological 
staging. This type of factor is not taken into consideration in the present tumor, node, 
metastasis (TNM) classification,2 mainly because of lack of data, small number of 
patients, or inconsistent clinical and pathologic results. As pulmonary nodules or vis-
ceral pleura invasion,3,4 lymphatic permeation might be a new T descriptor for a further 
revision of the staging system. Other potential changes are related to the size of the 
primary tumor, the number of positive descriptors within a T, N, or M category, or the 
number of metastases. This will nevertheless require the careful collection of adequate 
data with a sufficient number of cases for allowing multivariate analysis, taking into 
account all other significant descriptors.5 Data concerning the presence of carcinoma-
tous lymphangitis described in the area of the primary tumor, elsewhere within the lobe 
of the primary, and involving other areas within the ipsilateral and/or contralateral lung 
are currently collected in the International Association for the Study of Lung Cancer 
Staging Project.6
In terms of prognosis, multiple factors have been proposed, including tumor char-
acteristics, patients’ characteristics, tumor metabolic activity, laboratory parameters, 
and tumor biological markers.7 On the basis of the data available in the huge retrospective 
study performed for the 7th revision of the TNM system, the International Association 
for the Study of Lung Cancer staging committee proposed clinical extent of disease and 
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sex as potentially useful prognostic factors for patients with 
resectable NSCLC. Performance status and squamous cell 
type were proposed for stage IIB or superior and for stage 
IIIA, respectively. Considering pathological staging, age 
and sex were confirmed as important prognostic factors in 
addition to pathologic TNM category in surgically resected 
NSCLC.8 Standard uptake value maximum (SUVmax) of 
the primary tumor measured on fluorodeoxyglucose posi-
tron emission tomography scan was also included in the list 
of recommended prognostic factors.7 The evidence is based 
on more than 20 studies, all retrospective in nature that 
have assessed the prognostic value of the primary tumor 
SUV, a semiquantitative measurement of the tumor meta-
bolic activity. In a literature meta-analysis first published 
in 20089 and updated in 2010,10 SUV was found to be a 
potential prognostic factor for survival in the whole group 
of patients (stages I–IV; hazard ratio, 2.08; 95% confidence 
interval, 1.69–2.56), as well as for nonmetastatic tumors 
(stages I–III; hazard ratio, 2.18; 95% confidence interval, 
1.83–2.60) (Table 1). To assess the independent value of 
SUV, the same team performed an individual patient data 
meta-analysis, the first results of which were presented at 
the World Lung Cancer Conference 2013. In multivariate 
analysis, SUV confirmed its prognostic value in addition 
to age, stage, tumor size, and surgery. Other metabolic 
criteria are nowadays under investigation in NSCLC, con-
sidering the whole tumor burden either by measuring the 
“metabolic tumor volume” or the “total lesion glycolysis” 
(TLG). For example, a recent large retrospective study 
showed that metabolic tumor volume and TLG are inde-
pendent prognostic factors, at the difference of SUV, in 
stage III NSCLC,11 and the same conclusion was drawn for 
TLG in another retrospective study including only stage IV 
NSCLC.12
In addition, we need predictor factors for determining 
which patients might benefit from adjuvant chemotherapy. 
Today, the only factor used is the pathological stage on the 
basis of multiple randomized trials and meta-analyses.13–18 
Some biological markers such as mutS homolog 2 or excision 
repair cross-complementing 1, although promising in retro-
spective studies (summarized in Tables 1 and 2), failed mainly 
because no reproducible cutoff was found to decide which 
patients should be treated (Table 3). In this optic, anatomi-
cal factors such as lymphatic permeation or metabolic fac-
tors as measured on the primary tumor by positron emission 
tomography scan should be assessed in addition to pathologi-
cal stage by well-designed randomized trials with adequate 
sample sizes.
TABLE 1.  Prognostic Role of SUV in NSCLC
Study Year of Publication No. Patients % ADC Stage HR 95% CI
Ahuja 1998 155 ? I–IV 2.05 1.24–3.37
Sugawara 1999 38 50 I–IV 0.56 0.21–1.44
Vansteenkiste 1999 125 25 I–IIIB 2.72 1.50–4.94
Dhital 2000 77 23 ? 1.30 0.70–2.60
Higashi 2002 57 67 I–III 6.20 1.34–28.75
Jeong 2002 73 41 I–IV 4.33 1.80–10.45
Downey 2004 100 67 ? 2.60 1.02–6.64
Borst 2005 51 25 I–III 3.15 1.59–6.22
Cerfolio 2005 315 31 I–IV 2.65 1.63–4.31
Port 2005 64 88 ? 2.36 0.24–22.88
Sasaki 2005 162 46 I–III 7.66 1.41–41.50
Eschmann 2006 137 29 IIIA/IIIB 1.71 1.002.93
Prevost 2006 120 49 I–IV? 2.36 1.34–4.15
Raz 2006 36 0 ? 9.90 1.20–79.40
de Jong 2007 66 35 I–IIIA 2.93 1.21–7.09
Downey 2007 487 69 I–IV 1.58 1.05–2.40
Van Baardwijk 2007 102/46 30 I–IIIB 3.40 1.40–8.26
Zhang 2007 82 ? I–III 2.36 1.37–4.06
Goodgame 2008 136 52 I 1.89 1.20–2.99
Hanin 2008 97 47 I/II 2.83 1.52–5.26
Hoang 2008 214 38 IIIA/IIIB/IV 1.29 0.94–1.76
All studies 2591 2.08 1.69–2.56
Nonmetastatic stages 1612 2.18 1.83–2.60
Individual data and meta-analysis (reproduced with permission from the authors).
ADC, adenocarcinoma; HR, hazard ratio; CI, confidence interval; SUV, standard uptake value maximum; NSCLC, non–small-cell lung cancer; ?, unreported.
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